ALLOHA Trademark

Trademark Overview


On Friday, May 24, 2024, a trademark application was filed for ALLOHA with the United States Patent and Trademark Office. The USPTO has given the ALLOHA trademark a serial number of 98568310. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, March 27, 2025. This trademark is owned by TScan Therapeutics, Inc.. The ALLOHA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use for use in the treatment of cancer; pharmaceutical and biopharmaceutical T-cell receptor engineered preparations for use in the treatment of cancer; T-cell therapy products, namely, T-cell receptor engineered cells for medical use in the treatment of cancer

Pharmaceutical research and development in the field of T-cell therapy for the treatment of cancer; T-cell therapy research services, namely, pharmaceutical and scientific research in the field of treatment of cancer using T-cell receptor engineered T-cell therapies
alloha

General Information


Serial Number98568310
Word MarkALLOHA
Filing DateFriday, May 24, 2024
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateThursday, March 27, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 15, 2025

Trademark Statements


Goods and ServicesCells for medical or clinical use for use in the treatment of cancer; pharmaceutical and biopharmaceutical T-cell receptor engineered preparations for use in the treatment of cancer; T-cell therapy products, namely, T-cell receptor engineered cells for medical use in the treatment of cancer
Goods and ServicesPharmaceutical research and development in the field of T-cell therapy for the treatment of cancer; T-cell therapy research services, namely, pharmaceutical and scientific research in the field of treatment of cancer using T-cell receptor engineered T-cell therapies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 24, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, May 24, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTScan Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Friday, May 24, 2024NEW APPLICATION ENTERED
Monday, December 2, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 9, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 9, 2024NON-FINAL ACTION E-MAILED
Monday, December 9, 2024NON-FINAL ACTION WRITTEN
Monday, December 9, 2024ASSIGNED TO EXAMINER
Thursday, February 13, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 13, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 14, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 21, 2025EXAMINER'S AMENDMENT ENTERED
Friday, March 21, 2025EXAMINERS AMENDMENT E-MAILED
Friday, March 21, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 21, 2025EXAMINERS AMENDMENT -WRITTEN
Friday, March 21, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 9, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED